The FDA approval of the ACTPen was supported by data from 2 studies: an open-label, randomized, 2-period, crossover Phase 1 study (N=188), and an open-label, non-randomized, observational Phase 4 ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved ACTPen, a single-dose prefilled autoinjector of tocilizumab, for the treatment of adult ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved ACTPen™ ...

March 25, 2013 (Tokyo) - Chugai Pharmaceutical Co., Ltd. [Head Office: Chuo-ku Tokyo; Chairman & CEO: Osamu Nagayama (hereafter, "Chugai")] announced today that the subcutaneous injection formulation ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved the subcutaneous formulation of Actemra for the treatment of polyarticular juvenile ...

ZURICH, July 19 (Reuters) - Roche's Japanese subsidiary Chugai said on Tuesday subcutaneous injection of its Actemra drug has shown efficacy in rheumatoid arthritis compared to intravenous infusion.

Actemra (tocilizumab) is a prescription drug that’s used to treat certain conditions that affect your immune system. Actemra can cause side effects that range from mild to serious. Examples include ...

GenentechMedia:Joe St. Martin, 650-467-6800orInvestor:Thomas Kudsk Larsen, 650-467-2016Karl Mahler, 011 41 61 687 85 03 Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today ...

Actemra (tocilizumab) has been given an emergency use authorization (EUA). This EUA allows for in-hospital use of Actemra as a treatment for COVID-19 in certain cases. You should not take any ...

The FDA has approved Actemra® (tocilizumab; Genentech) subcutaneous injection for slowing the rate of decline in pulmonary function in SSc-ILD. The Food and Drug Administration (FDA) has approved ...